Recently, according to the information disclosed by the Shenzhen Stock Exchange, Sichuan MeCan Pharmaceutical Software Research and Development Co., Ltd. (hereinafter referred to as "MeCan Shares" or "MeCan Software") withdrew its listing application, and the sponsor, Dongxing Securities, withdrew its sponsorship. As a result, the Shenzhen Stock Exchange has decided to terminate its review of its initial public offering and listing on the GEM.
According to Beduo Finance, MeCan submitted a prospectus in June 2023 to be listed on the Growth Enterprise Market of the Shenzhen Stock Exchange, and originally planned to raise 435 million yuan, which will be used for disease diagnosis and treatment knowledge base product development projects, R&D center upgrade projects, as well as marketing service network and informatization projects.
According to the prospectus, MeCan is an enterprise specializing in the construction and maintenance of medical knowledge base, as well as the research and development, sales and technical services of clinical rational drug use systems. MeCan said in the prospectus that the company has been deeply engaged in the field of clinical rational drug use, providing customers with rational drug use information products and overall solutions covering the whole process of clinical diagnosis and treatment.
Tianyancha App shows that MeCan was established in May 1997 and is located in Chengdu, Sichuan Province. At present, the registered capital of the company is about 5,623 yuan, the legal representative is Lai Qi, and the shareholders include Sichuan Xinxin Meikang Information Technology Co., Ltd., Guanya Investment, Orient Securities Investment, etc.
At present, the main product of MeCan Co., Ltd. is the rational drug use system, which includes more than 220,000 domestic approved drug basic information and more than 87,000 domestic and foreign drug instructions, and manages more than 5,600 self-written drug monographs, more than 540 children's drug monographs, more than 900 pregnancy and lactation drug monographs, and more than 2 million drug review rules.
MeCan said in the prospectus that the MeCan pharmaceutical knowledge base consists of three professional databases, namely the basic drug information database, the medical information knowledge base and the medical review rules database. Among them, the data of the basic drug information database and the medical information knowledge base are regularly updated 10 times a year, and the data of the drug review rule database are regularly updated 4 times a year.
As of the end of the reporting period, MeCan had customers in 31 provinces, municipalities and autonomous regions across the country, covering more than 5,200 hospitals, accounting for more than 14% of the total number of hospitals in the country, including more than 1,200 tertiary hospitals, accounting for more than 70% of the national tertiary hospitals; Among the top 100 hospitals in Fudan's 2021 China Hospital Rankings, the company's products cover 61.
In 2020, 2021, 2022 and the first half of 2023, the revenue of MeCan shares will be 126 million yuan, 157 million yuan, 185 million yuan and 113 million yuan respectively, the net profit will be 38.7723 million yuan, 50.6617 million yuan, 72.3355 million yuan and 46.224 million yuan respectively, and the net profit after deducting non-profits will be 40.0395 million yuan, 46.8573 million yuan, 65.8578 million yuan and 41.9952 million yuan respectively.
According to the prospectus, the revenue of MeCan shares is mainly contributed by the clinical rational drug use system. During the reporting period, the company's revenue from the clinical rational drug use system was 94.565 million yuan, 118 million yuan, 144 million yuan and 87.5224 million yuan respectively, accounting for 74.98%, 75.08%, 77.83% and 77.68% of its main business income, respectively.
According to the prospectus, labor costs are the most important expense of MeCan shares. During the reporting period, the company's labor costs were 73.7767 million yuan, 96.1142 million yuan, 101 million yuan and 54.482 million yuan respectively (excluding share-based payment and employee remuneration in inventory), accounting for 76.29%, 79.47%, 79.96% and 77.76% of operating costs and period expenses respectively.
Bedo Finance found that MeCan shares have paid dividends many times. In 2020, 2021 and 2022, the company will pay cash dividends of 18.1275 million yuan, 38.71 million yuan and 12.00 million yuan respectively. In this regard, the Shenzhen Stock Exchange asked it to explain the reason and necessity of cash dividends in the inquiry letter; The reasonableness of not using its own funds to invest in fundraising projects.
Before the listing, the actual controller of MeCan shares was Lai Qi, who directly and indirectly controlled 49.86% of the voting rights, and served as the chairman and general manager of the company for a long time. Among them, Lai Qi directly holds 1.02% of the shares, and actually controls 48.84% of the voting rights of Meikang shares through Xinxin Meikang.
Before the IPO, Xinxin Meikang held 37.16% of the shares, Guangdong Guanyue held 16.37% of the shares, Suzhou Guanze held 9.49% of the shares, Zhixin Hechuang held 8.21% of the shares, Progus held 5.93% of the shares, Orient Securities Innovation held 5.47% of the shares, Kexing Siyuan held 4.65% of the shares, Xinhefu held 3.67% of the shares, and Zhili Kaixing held 3.47% of the shares.
At the same time, Jiaxing Tongren holds 2.37% of the shares, Chengdu Biocity holds 1.25% of the shares, Liu Yiyao holds 0.63% of the shares, and Chengda Juxing holds 0.23% of the shares.